Clinical trial
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT04925284
Study timeline
Study start (actual)2021-06-07Date precision: day
Registry last updated2025-04-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancerunresolved
Cervical Cancerunresolved
SCCHNunresolved
Pancreatic Cancerunresolved
Esophageal SCCunresolved
Triple Negative Breast Cancerunresolved
Hormone Receptor-positive Breast Cancerunresolved
Epithelial Ovarian Cancerunresolved
Endometrial Cancerunresolved
Tissue Factor-Expressing Solid Tumorsunresolved
Interventions
XB002DRUG
NivolumabDRUG · verified · RxNorm: nivolumab
BevacizumabDRUG · verified · RxNorm: bevacizumab
Sponsors & collaborators
Exelixislead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04925284 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.